SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that d...
* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibite...
SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported fina...
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...
SUZHOU, China, March 14, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...
SUZHOU, China, Feb. 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that ...
SUZHOU, China, Jan. 25, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and 3DMedicine...
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the f...
SUZHOU, China, Nov. 7, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...
* KN026 combined with docetaxel has significant efficacy in the first-line treatment of HER2-posi...
* KN046 showed encouraging efficacy result especially in OS benefit (mOS: 20.2 months) in advance...
SUZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...
* As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors...
SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmac...
SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...
SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced tha...
* As of August 18, 2022,the confirmed ORR for 55 evaluable subjects was 76.4% and DoR was 24.0 mo...
* As of Sep 10, 2022, 20 patients completed the surgery and pathological evaluation, tpCR rate we...